ALNYLAM PHARMACEUTICALS INC (DUL.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:DUL • US02043Q1076

268 EUR
-29.5 (-9.92%)
Last: Feb 10, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

Overall DUL gets a fundamental rating of 5 out of 10. We evaluated DUL against 81 industry peers in the Biotechnology industry. DUL has an average financial health and profitability rating. DUL is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year DUL was profitable.
  • DUL had a positive operating cash flow in the past year.
  • In the past 5 years DUL always reported negative net income.
  • In the past 5 years DUL reported 4 times negative operating cash flow.
DUL.DE Yearly Net Income VS EBIT VS OCF VS FCFDUL.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M -1B

1.2 Ratios

  • The Return On Assets of DUL (0.90%) is better than 72.84% of its industry peers.
  • DUL has a Return On Equity of 18.63%. This is amongst the best in the industry. DUL outperforms 87.65% of its industry peers.
  • DUL has a better Return On Invested Capital (5.65%) than 80.25% of its industry peers.
Industry RankSector Rank
ROA 0.9%
ROE 18.63%
ROIC 5.65%
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DUL.DE Yearly ROA, ROE, ROICDUL.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600

1.3 Margins

  • The Profit Margin of DUL (1.36%) is better than 74.07% of its industry peers.
  • DUL has a Operating Margin of 8.25%. This is in the better half of the industry: DUL outperforms 77.78% of its industry peers.
  • Looking at the Gross Margin, with a value of 83.90%, DUL is in the better half of the industry, outperforming 71.60% of the companies in the same industry.
  • DUL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 8.25%
PM (TTM) 1.36%
GM 83.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
DUL.DE Yearly Profit, Operating, Gross MarginsDUL.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), DUL is destroying value.
  • DUL has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for DUL has been increased compared to 5 years ago.
  • DUL has a better debt/assets ratio than last year.
DUL.DE Yearly Shares OutstandingDUL.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DUL.DE Yearly Total Debt VS Total AssetsDUL.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

  • An Altman-Z score of 5.16 indicates that DUL is not in any danger for bankruptcy at the moment.
  • DUL's Altman-Z score of 5.16 is fine compared to the rest of the industry. DUL outperforms 77.78% of its industry peers.
  • DUL has a debt to FCF ratio of 11.32. This is a negative value and a sign of low solvency as DUL would need 11.32 years to pay back of all of its debts.
  • DUL's Debt to FCF ratio of 11.32 is fine compared to the rest of the industry. DUL outperforms 77.78% of its industry peers.
  • DUL has a Debt/Equity ratio of 10.22. This is a high value indicating a heavy dependency on external financing.
  • DUL's Debt to Equity ratio of 10.22 is on the low side compared to the rest of the industry. DUL is outperformed by 67.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.22
Debt/FCF 11.32
Altman-Z 5.16
ROIC/WACC0.47
WACC12.15%
DUL.DE Yearly LT Debt VS Equity VS FCFDUL.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

  • DUL has a Current Ratio of 2.54. This indicates that DUL is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.54, DUL perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
  • DUL has a Quick Ratio of 2.49. This indicates that DUL is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.49, DUL is in the better half of the industry, outperforming 60.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 2.49
DUL.DE Yearly Current Assets VS Current LiabilitesDUL.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • DUL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 119.47%, which is quite impressive.
  • Looking at the last year, DUL shows a very strong growth in Revenue. The Revenue has grown by 53.24%.
  • The Revenue has been growing by 59.21% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)119.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%342.53%
Revenue 1Y (TTM)53.24%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%149.35%

3.2 Future

  • Based on estimates for the next years, DUL will show a very strong growth in Earnings Per Share. The EPS will grow by 72.94% on average per year.
  • The Revenue is expected to grow by 34.81% on average over the next years. This is a very strong growth
EPS Next Y212.2%
EPS Next 2Y125.55%
EPS Next 3Y99.91%
EPS Next 5Y72.94%
Revenue Next Year67.95%
Revenue Next 2Y55.69%
Revenue Next 3Y45.96%
Revenue Next 5Y34.81%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DUL.DE Yearly Revenue VS EstimatesDUL.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
DUL.DE Yearly EPS VS EstimatesDUL.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 623.26, the valuation of DUL can be described as expensive.
  • Based on the Price/Earnings ratio, DUL is valued a bit cheaper than the industry average as 72.84% of the companies are valued more expensively.
  • DUL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.03.
  • With a Price/Forward Earnings ratio of 47.55, DUL can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, DUL is valued a bit cheaper than 74.07% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of DUL to the average of the S&P500 Index (27.97), we can say DUL is valued expensively.
Industry RankSector Rank
PE 623.26
Fwd PE 47.55
DUL.DE Price Earnings VS Forward Price EarningsDUL.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 200 400 600

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DUL indicates a somewhat cheap valuation: DUL is cheaper than 71.60% of the companies listed in the same industry.
  • 76.54% of the companies in the same industry are more expensive than DUL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 190.11
EV/EBITDA 134.34
DUL.DE Per share dataDUL.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DUL does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as DUL's earnings are expected to grow with 99.91% in the coming years.
PEG (NY)2.94
PEG (5Y)N/A
EPS Next 2Y125.55%
EPS Next 3Y99.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DUL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALNYLAM PHARMACEUTICALS INC

FRA:DUL (2/10/2026, 7:00:00 PM)

268

-29.5 (-9.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30
Earnings (Next)02-12
Inst Owners99.97%
Inst Owner ChangeN/A
Ins Owners0.2%
Ins Owner ChangeN/A
Market Cap35.41B
Revenue(TTM)3.21B
Net Income(TTM)43.56M
Analysts79.44
Price Target441.79 (64.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)103.88%
Min EPS beat(2)30.6%
Max EPS beat(2)177.15%
EPS beat(4)3
Avg EPS beat(4)65.69%
Min EPS beat(4)-2.21%
Max EPS beat(4)177.15%
EPS beat(8)7
Avg EPS beat(8)53.79%
EPS beat(12)10
Avg EPS beat(12)49.23%
EPS beat(16)10
Avg EPS beat(16)28.59%
Revenue beat(2)2
Avg Revenue beat(2)20.36%
Min Revenue beat(2)15.49%
Max Revenue beat(2)25.23%
Revenue beat(4)2
Avg Revenue beat(4)9.94%
Min Revenue beat(4)-0.56%
Max Revenue beat(4)25.23%
Revenue beat(8)4
Avg Revenue beat(8)11.04%
Revenue beat(12)7
Avg Revenue beat(12)14.54%
Revenue beat(16)8
Avg Revenue beat(16)8.99%
PT rev (1m)12.27%
PT rev (3m)N/A
EPS NQ rev (1m)-5.16%
EPS NQ rev (3m)N/A
EPS NY rev (1m)30.04%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 623.26
Fwd PE 47.55
P/S 13.11
P/FCF 190.11
P/OCF 158.29
P/B 179.92
P/tB 179.92
EV/EBITDA 134.34
EPS(TTM)0.43
EY0.16%
EPS(NY)5.64
Fwd EY2.1%
FCF(TTM)1.41
FCFY0.53%
OCF(TTM)1.69
OCFY0.63%
SpS20.44
BVpS1.49
TBVpS1.49
PEG (NY)2.94
PEG (5Y)N/A
Graham Number3.8
Profitability
Industry RankSector Rank
ROA 0.9%
ROE 18.63%
ROCE 8.03%
ROIC 5.65%
ROICexc 32.6%
ROICexgc 32.6%
OM 8.25%
PM (TTM) 1.36%
GM 83.9%
FCFM 6.9%
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 10.22
Debt/FCF 11.32
Debt/EBITDA 7.44
Cap/Depr 79.01%
Cap/Sales 1.39%
Interest Coverage 2.25
Cash Conversion 82.82%
Profit Quality 508.12%
Current Ratio 2.54
Quick Ratio 2.49
Altman-Z 5.16
F-Score5
WACC12.15%
ROIC/WACC0.47
Cap/Depr(3y)112.53%
Cap/Depr(5y)140.08%
Cap/Sales(3y)3.96%
Cap/Sales(5y)7.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)119.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%342.53%
EPS Next Y212.2%
EPS Next 2Y125.55%
EPS Next 3Y99.91%
EPS Next 5Y72.94%
Revenue 1Y (TTM)53.24%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%149.35%
Revenue Next Year67.95%
Revenue Next 2Y55.69%
Revenue Next 3Y45.96%
Revenue Next 5Y34.81%
EBIT growth 1Y240.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year558.53%
EBIT Next 3Y169.14%
EBIT Next 5Y135.27%
FCF growth 1Y432.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13193.2%
OCF growth 3YN/A
OCF growth 5YN/A

ALNYLAM PHARMACEUTICALS INC / DUL.DE FAQ

Can you provide the ChartMill fundamental rating for ALNYLAM PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to DUL.DE.


What is the valuation status of ALNYLAM PHARMACEUTICALS INC (DUL.DE) stock?

ChartMill assigns a valuation rating of 4 / 10 to ALNYLAM PHARMACEUTICALS INC (DUL.DE). This can be considered as Fairly Valued.


What is the profitability of DUL stock?

ALNYLAM PHARMACEUTICALS INC (DUL.DE) has a profitability rating of 4 / 10.


Can you provide the financial health for DUL stock?

The financial health rating of ALNYLAM PHARMACEUTICALS INC (DUL.DE) is 5 / 10.